Mabylon develops novel antibody therapeutics in immunology & inflammation (I&I) and neurological disorders.
Mabylon has raised $18.6M in total funding. The most recent round was Undisclosed. The last funding was announced in August 2025.
Mabylon's investors include Innosuisse, The ALS Association, Target ALS Foundation.
Mabylon is headquartered in Schlieren, Switzerland.
Mabylon develops novel antibody therapeutics in immunology & inflammation (I&I) and neurological disorders.
Mabylon is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mabylon — Funding & Investors." VCBacked, August 12, 2025, https://www.vcbacked.co/company/mabylon. Accessed September 30, 2026.
VCBacked. (2025). Mabylon — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/mabylon
{{cite web |title=Mabylon — Funding & Investors |url=https://www.vcbacked.co/company/mabylon |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated